B1Flagship platform
Protein engineering · Fibrinolytic variants
Rank hundreds of variants without purifying each one. A cell-free expression platform scores
staphylokinase variants by activity directly from unpurified reactions — built for engineering
campaigns where variant numbers make conventional screening impractical.
- Cell-free screening
- High-throughput ranking
- Protein engineering
- Evidence
- Publication reported 2026 · data package under NDA
- Stage
- Pilot-ready · co-development open
- Indicative
- € 12 000 – 60 000co-development quoted individually
B2
Enzyme engineering · Directed evolution
Carbon–halogen bond cleavage for remediation and industrial process chemistry. Directed
evolution, ribosome display and catalytic optimisation applied to your substrate — relevant
wherever a process generates or handles halogenated streams.
- Biocatalysis
- Bioremediation
- Green chemistry
- Evidence
- Capability & method data under NDA
- Stage
- Pilot-ready · licensing open
- Indicative
- € 15 000 – 120 000negotiable by scope and application
B3
Protein biophysics · Formulation support
Know before you formulate. DSC, fluorescence probes and dynamic light scattering map
thermodynamic and kinetic stability; buffer, salt and pH screening and aggregation risk
profiling are run on your protein rather than on a generic prediction.
- Thermal stability
- Aggregation risk
- Buffer optimisation
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready
- Indicative
- € 8 000 – 50 000negotiable by scope and application
B4
Protease activity · Condition optimisation
Kosmotropic anions increase HRV 3C protease rigidity, stability and catalytic efficiency — a
published finding with direct workflow consequences. If your production depends on a cleavage
step, this tells you which conditions maximise yield and enzyme lifetime.
- Protease workflow
- Salt screening
- Enzyme stability
- Evidence
- Peer-reviewed 2022 (Biophys. Chem.)
- Stage
- Pilot-ready
- Indicative
- € 6 000 – 35 000negotiable by scope and application
B5
Recombinant protein purification
One-step affinity purification and immobilisation for MBP-tagged proteins. The MBP tag
substantially improves solubility for difficult-to-express fusion partners — a cost-effective
alternative for teams spending too much on multi-step chromatography of insoluble targets.
- MBP tag
- Enhanced solubility
- One-step purification
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready
- Indicative
- € 5 000 – 40 000negotiable by scope and application
B6
Membrane protein · GPCR
High-risk, high-reward targets made more tractable: candidate selection, expression and
purification strategy, hot-spot identification, and yeast or ribosome display for solubility
improvement. Feasibility first — before you commit a full GPCR budget.
- GPCR
- Membrane proteins
- Drug discovery
- Evidence
- Feasibility assessment · under NDA
- Stage
- Feasibility → pilot · licensing open
- Indicative
- € 15 000 – 120 000negotiable by scope and application
B7
Aggregation · Self-assembly
Aggregation quietly kills promising protein therapeutics and formulations. The platform screens
stress conditions, maps aggregation kinetics and identifies stabilisation strategies. It also
covers spider-silk self-assembly systems for biomedical and biomaterial applications.
- Aggregation assay
- Neurodegeneration research
- Advanced biomaterials
- Evidence
- Method portfolio · report under NDA
- Stage
- Pilot-ready · licensing open
- Indicative
- € 8 000 – 60 000negotiable by scope and application
